For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for International Business Machines Corporation (IBM) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Watch · Gem Score -2 (−100…+100 Quality+Value blend) · Quality 36 · Value -33 · Sentiment -55 (timing only, not weighted) · Composite fair value $209.37 vs $223.65 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
International Business Machines Corporation
IBM NYSEInternational Business Machines Corporation is a multinational technology and consulting company based in Armonk, New York. It provides integrated information technology solutions that combine software, services, and infrastructure for enterprise and government clients worldwide. Today, International Business Machines Corporation focuses on areas such as hybrid cloud, artificial intelligence, data and analytics, cybersecurity, and automation, delivering end-to-end platforms and expertise to support complex IT and business operations. The company organizes its activities into four main segments: software, consulting, infrastructure, and financing, allowing it to address a broad range of digital transformation, modernization, and operational resilience needs. International Business Machines Corporation plays a significant role in critical sectors including financial services, manufacturing, healthcare, transportation, and the public sector, where reliable IT services, enterprise software, and large-scale systems integration are essential to daily operations. Founded in 1911 and headquartered in the United States, it operates in more than 170 countries and remains a central provider of enterprise technology solutions across global markets.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 11.17
Total Equity: $32.74B
Shares: 948,675,228
Total Debt: $61.26B
Cash: $13.59B
EBITDA: $13.14B
Total Debt: $61.26B
Cash: $13.59B
Revenue: $67.54B
Revenue: $67.54B
Revenue: $67.54B
Total Equity: $32.74B
Tax Rate: -2.3%
Equity: $32.74B
Total Debt: $61.26B
Cash: $13.59B
Current Liabilities: $38.66B
Long-Term Debt: $54.84B
Total Debt: $61.26B
Total Equity: $32.74B
Shares: 948,675,228
Shares: 948,675,228
CapEx: -$1.09B
Shares: 948,675,228
Stock Price: $223.65
Net Income: $10.59B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 1, 2026 6:25pm (22d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $57.4B | $60.5B | $61.9B | $62.8B | $67.5B |
| Cost of Revenue | $25.9B | $27.8B | $27.6B | $27.2B | $28.2B |
| Gross Profit | $31.5B | $32.7B | $34.3B | $35.6B | $39.3B |
| Operating Expenses | $25.2B | $25.2B | $25.8B | $27.2B | $28.4B |
| Operating Income | $6.3B | $7.5B | $8.5B | $8.4B | $10.9B |
| Net Income | $5.7B | $1.6B | $7.5B | $6.0B | $10.6B |
| EBITDA | $10.1B | $9.9B | $10.6B | $10.6B | $13.1B |
| EPS | $6.41 | $1.82 | $8.23 | $6.53 | $11.36 |
| EPS (Diluted) | $6.35 | $1.80 | $8.14 | $6.43 | $11.17 |
Balance Sheet (Annual)
Last updated: Jul 31, 2026 9:17am (23d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $6.7B | $7.9B | $13.1B | $13.9B | $13.6B |
| Total Current Assets | $29.5B | $29.1B | $32.9B | $34.5B | $36.9B |
| Total Assets | $132.0B | $127.2B | $135.2B | $137.2B | $151.9B |
| Current Liabilities | $33.6B | $31.5B | $34.1B | $33.1B | $38.7B |
| Long-Term Debt | $44.9B | $46.2B | $50.1B | $49.9B | $54.8B |
| Total Liabilities | $113.0B | $105.2B | $112.6B | $109.8B | $119.1B |
| Total Equity | $19.0B | $22.0B | $22.6B | $27.4B | $32.7B |
| Retained Earnings | $154.2B | $149.8B | $151.3B | $151.2B | $155.6B |
Cash Flow (Annual)
Last updated: Aug 1, 2026 6:25pm (22d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $12.8B | $10.4B | $13.9B | $13.4B | $13.2B |
| Capital Expenditure | -$2.1B | -$1.3B | -$1.2B | -$1.0B | -$1.1B |
| Free Cash Flow | $10.7B | $9.1B | $12.7B | $12.4B | $12.1B |
| Acquisitions (net) | -$3.3B | -$2.3B | -$5.1B | -$3.3B | -$8.3B |
| Net Debt Issued / (Repaid) | -$8.6B | -$6.8B | -$5.1B | -$6.6B | -$5.5B |
| Dividends Paid | -$5.9B | -$5.9B | -$6.0B | -$6.1B | -$6.3B |
| Stock Buybacks | — | — | — | — | — |
| Net Change in Cash | -$6.7B | $1.0B | $5.1B | $1.1B | -$520.0M |
Growth Trends (YoY %)
Last updated: Aug 1, 2026 6:25pm (22d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +5.5% | +2.2% | +1.4% | +7.6% |
| Gross Profit Growth | +3.8% | +4.9% | +3.6% | +10.5% |
| Operating Income Growth | +20.1% | +13.5% | -1.6% | +29.5% |
| Net Income Growth | -71.5% | +357.7% | -19.7% | +75.9% |
| EBITDA Growth | -2.2% | +7.2% | -0.7% | +24.5% |
Dividend History (Last 20)
Last updated: Jul 31, 2026 9:17am (23d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-05-08 | $1.69 | — | — | — |
| 2026-02-10 | $1.68 | — | — | — |
| 2025-11-10 | $1.68 | — | — | — |
| 2025-08-08 | $1.68 | — | — | — |
| 2025-05-09 | $1.68 | — | — | — |
| 2025-02-10 | $1.67 | — | — | — |
| 2024-11-12 | $1.67 | — | — | — |
| 2024-08-09 | $1.67 | — | — | — |
| 2024-05-09 | $1.67 | — | — | — |
| 2024-02-08 | $1.66 | — | — | — |
| 2023-11-09 | $1.66 | — | — | — |
| 2023-08-09 | $1.66 | — | — | — |
| 2023-05-09 | $1.66 | — | — | — |
| 2023-02-09 | $1.65 | — | — | — |
| 2022-11-09 | $1.65 | — | — | — |
| 2022-08-09 | $1.65 | — | — | — |
| 2022-05-09 | $1.65 | — | — | — |
| 2022-02-10 | $1.64 | — | — | — |
| 2021-11-09 | $1.64 | — | — | — |
| 2021-08-09 | $1.57 | — | — | — |
Deep Analysis
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-19 08:59Even the bull case prices 15% below today — the ratio here measures the model-vs-market gap, not payoff odds. Another quarter like the worst recent one costs 40%.
| Case | Growth | Margin | Fair value | vs price ($223.65) |
|---|---|---|---|---|
| Bull — recovery | +8% | 17.9% | $189.85 | -15% |
| Base — stabilizes | +5% | 15.5% | $153.61 | -31% |
| Bear — keeps slipping | +3% | 13.2% | $122.00 | -45% |
| Stress — last quarter repeats | +1% | 15.5% | $134.00 | -40% |
Narrative Economics
market-narrative step).
Claude Reading
Looking at the raw quarterly print first: 2026-Q2 revenue of $17.16B is +1.1% YoY vs. 2025-Q2's $16.98B, and 2026-Q1 at $15.92B is +9.5% YoY vs. $14.54B. That's noisy — Q1 comps were flattered by a weak year-ago base. The trailing four quarters sum to ~$69.1B against 2025 calendar-year revenue of $67.54B, so run-rate growth is roughly 2-3%, not the 4.5% CAGR headline. The Q4-2025 net margin of 28.4% ($5.6B NI on $19.69B) is an obvious outlier — likely tax/one-time driven — and it inflates the 18.8% earnings CAGR and 75.9% recent earnings YoY figures the momentum module is quoting. Strip that out and normalized earnings growth is more like high-single-digits. The synthesis is being seduced by a lumpy quarter.
The balance sheet deserves more skepticism than the models give it. $61.26B debt against $32.74B equity (D/E 1.87) and a current ratio of 0.96 is not a "mature earner" fortress — it's a leveraged FCF machine where the 3.0% dividend yield with a 59% payout ratio consumes a meaningful chunk of the $12.1B FCF (roughly $6.3B in dividends). FCF has actually compounded at *negative* 2.3% over the measurement window, which directly contradicts the "steady compounder" narrative archetype. ROE of 32.4% looks flattering until you notice it's leverage-inflated; ROIC at 13.8% and ROA at 6.97% are the honest numbers, and they're fine but not exceptional for something trading at 3.14x sales and 19.6x EV/EBITDA. Those multiples are software-adjacent, not services-adjacent.
I largely agree with the Thesis Evaluation's -8 skew and disagree with the Synthesis's "slight upside to $234." The signal-adjusted fair value of $234 leans on projected growth re-acceleration that the deceleration flag in Revenue Confidence directly contradicts. A contrarian read: IBM is being valued as if the Red Hat/software mix shift is a done deal, but Red Hat's growth has been decelerating industry-wide as hyperscalers bundle Kubernetes/OpenShift alternatives, and IBM doesn't disclose Red Hat cleanly enough to disprove that. Meanwhile, the Consulting segment (~$21B of revenue) is directly in the crosshairs of generative AI — Accenture has already guided cautiously, and IBM's own watsonx narrative hasn't produced disclosed revenue traction commensurate with the multiple. The Pre-Flight framing of "20x reflecting skepticism mixed with hope" is right, but hope is doing more work than the Narrative module ("minimal intensity") admits. If software mix stalls at ~45% and consulting decays 2-3%, you're paying 20x for a 2% grower with leverage.
Where the models are thin: nobody stress-tested that Q4-2025 margin outlier, nobody flagged the negative FCF CAGR against the "Strong Cash Flow Quality" tag (those are in direct tension), and the Market Forces module simply failed. The "Above Sector Benchmarks" sector intelligence is doing unearned lifting — IBM's ROIC of 13.8% is below Microsoft, Oracle, and even Accenture on a comparable basis. My fair-value read: apply 16-17x to normalized ~$11B earnings (ex-Q4 windfall) = $176-187B equity value, or roughly $187-198/share. That's 12-16% downside from $223.65, not 5% upside. The 3% dividend cushions the drawdown but doesn't reverse the math. I dissent from the "slight_upside" verdict — the synthesis is anchoring on a composite that includes a signal-adjustment kicker for growth re-rating that the underlying deceleration doesn't support. This is a hold-if-you-own-it-for-the-yield name, not an accumulate name at $224. Entry gets interesting sub-$195; table-pounding sub-$175 where you're paid 3.5%+ to wait on the watsonx/Red Hat option.
GPT Reading
IBM’s numbers finally look better than the long-running “legacy value trap” caricature, but the stock already reflects that improvement. Revenue has gone from $57.35B in 2021 to $67.54B in 2025, a respectable 4.2%-4.5% annual clip for a company of this size, while operating income rose from $6.25B to $10.86B and net income from $5.74B to $10.59B. That is not financial engineering alone; gross margin expanded from 54.9% in 2021 to 58.2% in 2025, and operating margin from 10.9% to 16.1%. The quarterly pattern also supports a business with real, if unspectacular, forward motion: first-half 2026 revenue was $33.08B versus $31.52B in first-half 2025, up about 5%, and net income was $3.39B versus $3.25B, up about 4%. In other words, IBM is growing, and margins are holding. The problem is that a $210.7B market cap for a company generating $12.10B of free cash flow and growing low single digits is no bargain.
What stands out most is that the valuation now asks investors to pay for consistency as if it were scarcity. At $223.65, IBM trades around 20.0x earnings, 3.14x sales, 19.6x EV/EBITDA, and roughly 17.4x trailing free cash flow. Those are acceptable multiples for a durable software-heavy platform with cleaner balance sheet optionality, but IBM still carries $61.26B of debt against $13.59B of cash and a current ratio below 1.0. Net debt is substantial, and while the dividend is covered, the payout ratio near 59% means capital allocation flexibility is not enormous. Return metrics look healthy — 32.4% ROE and 13.8% ROIC — but the ROE is flattered by leverage and a relatively modest $32.74B equity base. This is a mature franchise getting paid close to a premium multiple without premium growth.
There is also more noise in the earnings quality than the headline momentum suggests. Net income has been lumpy: 2024 included a September quarter with a $330M loss, then 2025 closed with a $5.60B December-quarter profit and a full-year net margin of 15.7%, far above prior years. That kind of swing says investors should anchor more on cash generation and operating income than quarterly EPS optics. On that lens, IBM is solid but not accelerating dramatically. Free cash flow of $12.10B is strong, yet the multi-year FCF trend is not a breakout story, especially compared with the much stronger earnings CAGR. If earnings are compounding high-teens while FCF is down modestly over the same broad period, some of the improvement is mix, accounting, and margin normalization rather than a business entering a new growth regime. I see a better IBM than three years ago, but not one that obviously deserves multiple expansion from here.
The best argument against this cautious read is straightforward: IBM may have crossed the threshold from restructuring story to reliable compounder, and the market may still be underestimating that durability. A business that can grow revenue from $62.75B to $67.54B in one year, expand operating income by nearly $2.5B, and convert $13.19B of operating cash flow into $12.10B of free cash flow with just $1.09B of capex is a very powerful machine. If that model sustains even 5%-6% revenue growth with operating margins staying around 16%, then 20x earnings is not expensive, especially for a large-cap tech name with a 3.0% dividend yield and defensive enterprise exposure. The first-half 2026 numbers do not show deterioration; they show continued execution. A bull would also point out that 17x-18x FCF for a stable, improving, mission-critical enterprise vendor is hardly euphoric in today’s market.
What would change my mind is evidence that IBM can turn this from a margin-led repair into a durable growth-plus-cash story. Specifically, I would want to see full-year revenue growth stay above 5% while free cash flow grows clearly above earnings noise — ideally toward $13B-$14B annualized without balance-sheet strain. If second-half 2026 can lift annual revenue toward roughly $70B and preserve operating margin around 16%-17%, then today’s price would look more justified and even a bit cheap. Conversely, if growth slips back toward 2%-3%, or if FCF stalls around $12B while leverage remains elevated, the stock should trade more like a mature services incumbent, which to me implies closer to 15x-17x earnings and a share price below $200.
Grok Reading
IBM’s 2025 results mark a genuine inflection, not cosmetic improvement. Revenue climbed to $67.54B from $62.75B (+7.6%), the strongest annual print in the five-year series, while operating income expanded to $10.86B and net income nearly doubled to $10.59B. Gross margin held at 58.2% and operating margin reached 16.1%, consistent with a mix shift toward higher-value software. Free cash flow of $12.10B on only $1.09B of capex underscores the cash-conversion quality of the franchise; the 3.0% dividend (59% payout) is comfortably covered. Early 2026 has not reversed the trend: Q1 revenue of $15.92B was up 9.5% year-on-year and Q2 held at $17.16B. At 20× trailing earnings, 3.1× sales and 19.6× EV/EBITDA, the market is still capitalizing IBM as a near-zero-growth cash machine, yet the recent top-line acceleration and 18.8% earnings CAGR imply the hybrid-cloud/Red Hat engine is finally contributing measurable dollars rather than slide-ware.
The balance-sheet leverage is real—$61.3B of debt against $13.6B cash and a current ratio of 0.96—but ROE of 32% and ROIC of 13.8% show the capital is being put to work. The valuation synthesis composite at roughly $234 already sits only 5% above the $224 quote; the gap is narrow because the market refuses to pay a software multiple until Software demonstrably exceeds half the mix. That skepticism is priced; the 2025 step-function in both revenue and free cash flow is not.
The strongest counter-argument is that 2025’s earnings quality is inflated by an anomalous Q4. Net margin spiked to 28.4% on $19.69B of revenue, producing $5.60B of the year’s $10.59B profit—an outlier versus the 7–13% range in surrounding quarters. Strip that quarter and the underlying run-rate looks closer to the mid-single-digit growth the bears claim. Free-cash-flow CAGR remains negative at –2.3% over the longer window, quarterly revenue growth is already decelerating, and consulting remains exposed to AI-driven headcount compression and hyperscaler bundling of Red Hat alternatives. At 1.87× debt-to-equity the balance sheet leaves little room for a mis-step; any re-acceleration of legacy attrition would quickly pressure both the dividend and the multiple.
I would reverse to a clear overvalued stance if the next two quarters show revenue growth slipping back below 3% while Software mix stalls, or if free cash flow falls below $10B annualized. Conversely, two consecutive quarters of double-digit Software growth that lifts the overall top line above 8% with stable 16%+ operating margins would justify a re-rating toward the mid-$250s and force a higher conviction bull case.
Big-3 Panel — where each AI stands
Claude — Second Response · overvalued revised
VERDICT: Fairly valued to modestly overvalued; fair value $195-210 vs $223.65 — accept the top-line acceleration, reject the software re-rating until Red Hat disclosure or FCF confirms it
The Q4-2025 outlier is the crux, and both colleagues actually concede it — GPT explicitly notes the "$5.60B December-quarter profit" and lumpy pattern, and Grok grants that stripping Q4 puts underlying growth "closer to the mid-single-digit growth the bears claim." So on the central quality-of-earnings point, I'm not moved because they haven't rebutted it — they've absorbed it. What I do need to concede to Grok is that 2025 revenue of $67.54B vs $62.75B is +7.6%, not the 2-3% run-rate I anchored on from the trailing-four-quarter sum. That's a real number and I underweighted it. GPT's framing of first-half 2026 at $33.08B vs $31.52B (+5%) is also a fair check on my "deceleration" reading — it's decelerating from the 2025 print but still above the 2-3% I implied.
What doesn't move me: Grok's leap from "Software may exceed half the mix" to a mid-$250s re-rating requires evidence that isn't in the data — IBM's own disclosure doesn't cleanly separate Red Hat organic growth, and hyperscaler competitive pressure on OpenShift is a real, unquantified overhang. GPT's more disciplined framing — "I'd need sub-$200 or clear path to $13B+ FCF" — is essentially my position with a slightly softer fair-value anchor. The negative FCF CAGR against rising reported earnings remains the tell that neither colleague fully reconciles: if this were a genuine software-mix inflection, FCF should be leading earnings, not lagging.
Revising modestly. Accepting the 5-7% revenue tape as more real than I initially credited, I'll widen my fair-value range to $195-210 (17-18x normalized ~$10.5-11B earnings), which acknowledges the top-line acceleration without paying for a re-rating that requires disclosure IBM doesn't provide. That's fairly-valued-to-modestly-overvalued rather than clearly overvalued. Still not a buyer at $224; the asymmetry favors waiting.
GPT — Second Response · overvalued changed direction
VERDICT: Modestly overvalued at $223.65; fair value looks closer to $190-$205 unless IBM proves normalized 5%+ growth and $13B+ free cash flow.
Claude’s critique moved me more than Grok’s optimism, mainly because it attacks the exact weak points in my first read with better normalization. The most important point is the Q4-2025 earnings outlier: $5.6B of net income on $19.69B revenue is too abnormal to lean on when discussing an 18.8% earnings CAGR or a 20x trailing P/E. I had already flagged earnings quality as noisy, but Claude is right that the market and some model outputs may be over-crediting that quarter. His second useful correction is on growth: first-half 2026 looks fine, but the underlying run-rate is closer to 2%-3% than a clean mid-single-digit reacceleration if you smooth the comps. That matters because IBM’s current multiple only feels acceptable if the business is truly graduating into a durable 5%-6% grower with rising FCF. I also think his framing of the FCF contradiction is fair: a business described as a steady compounder should not have a negative multi-year FCF CAGR without a stronger explanation.
What did not move me is the more bullish “inflection” case. Grok is right that IBM is a better business than the old value-trap narrative, and I still respect the margin gains, cash conversion, and resilience. But the stock is not priced like a broken incumbent; it is already priced like a credible software-tilted platform. At ~17x trailing FCF and ~20x earnings, with leverage still material and consulting/red-hat mix questions unresolved, I no longer think “fairly valued to slightly overvalued” is the cleanest expression. I’m revising modestly toward a clearer overvalued stance, though not to deep downside: the business quality improvement is real enough to prevent me from going fully bearish. My workable range is roughly $190-$205 absent evidence of sustained >5% organic growth and FCF moving decisively above $13B.
Grok — Second Response · fairly valued changed direction
VERDICT: Fairly valued at $224; normalized 2-3% growth and FCF trend cap fair value at $210-225
The Q4-2025 margin spike and the true run-rate growth numbers are the arguments that forced a revision. Claude’s isolation of the $5.6 B net-income outlier (28.4 % margin) correctly deflates the 18.8 % earnings CAGR I had leaned on; once that quarter is normalized, trailing earnings sit closer to high-single-digits and the 20× multiple no longer looks like a discount to a hybrid-cloud compounder. GPT’s first-half 2026 arithmetic (revenue +5 %, net income +4 %) and the explicit Q2 deceleration to +1.1 % YoY further undercut the “inflection” narrative I originally accepted. Negative multi-year FCF CAGR of –2.3 % against a 59 % payout and 1.87× leverage is not the fortress cash machine that justified low-$240s; it is a mature earner already priced for the improvement it has delivered.
I still reject Claude’s $187–198 fair-value band. Applying 16–17× to a fully stripped earnings base ignores the durable $12 B FCF, 58 % gross margins, and the fact that operating income has expanded nearly $2.5 B since 2021 with only $1 B of capex. That franchise quality keeps the floor nearer $205–210 rather than the deep-value zone. But the gap between my original low-$240s and today’s $224 has closed: the market is already capitalizing the better IBM, and further re-rating requires the software-mix proof I had treated as imminent.
Two clean quarters of >5 % revenue growth and FCF moving through $13 B would restore upside; anything less leaves the stock range-bound.
Advanced Analysis Forensic deep-dive · separate lenses
IBM presents as a healthy mature_earner in visible re-acceleration. Revenue climbed from 57.4B in 2021 to 67.5B in 2025, with gross margin expanding meaningfully from 54.9% to 58.2% and operating margin lifting from 10.9% to 16.1%. Net income nearly doubled from 5.74B in 2023 to 10.59B in 2025, and FCF has stayed anchored around 10-12B annually, with OCF/NI at 2.79x and accruals at -4.8% of assets - both signs that reported profit is genuinely cash-backed. Beneish M of -2.39 and Altman Z of 3.16 corroborate clean earnings quality with no mechanical red flags. The soft spots are structural rather than acute. Net debt sits at roughly -47.7B against only 13.6B liquid cash, so the balance sheet is a constraint, not a cushion - fine for a business throwing off 12B FCF, but it limits optionality and makes the company sensitive to rate and refinancing conditions. Diluted share count has crept from 904.6M to 948.7M (about 1.2% CAGR) with SBC at 2.5% of revenue and effectively no net buyback offset, meaning per-share value is being modestly diluted rather than compounded. This is a business getting better across profitability and cash conversion, but not one that yet demonstrates fortress-level capital discipline or per-share compounding.
Verify before trusting this (5)
- Nature of 2022 net income compression (5.74B to 1.64B) - was it a pension settlement, Kyndryl separation charge, or impairment?
- Debt maturity ladder and weighted average coupon on the 60B+ gross debt stack
- Software vs consulting vs infrastructure segment mix and margin contribution behind the 330 bps GM expansion
- Recent M&A cadence (HashiCorp, Red Hat integration status) and goodwill as % of assets
- Pension obligation status and any recurring mark-to-market items affecting GAAP earnings
The composite fair value of $216.80 sits 3% below the $223.65 price, and the signal-adjusted $234.15 sits 5% above - a tight band straddling today's quote. The three underlying methods disagree sharply: DCF at $276.34 (implying 24% upside), anchored P/E at $188.96 (implying 15% downside), and an EPV floor at $125.56 (a stress case, not a base case). The wide dispersion tells me the deserved value is genuinely uncertain, but the center of gravity is essentially the current price. Quality is solid (grade 36) and earnings are clean, which supports paying a full multiple - but a full multiple is what you are paying.
Verify before trusting this (4)
- Red Hat and software segment organic growth rate in latest 10-Q - is the $25B+ platform revenue actually compounding?
- Consulting segment trajectory - is legacy decay accelerating or stabilizing?
- FCF guidance for the year vs the $12B run-rate assumed in the DCF
- Any change in buyback posture that would offset the 1.2% annual dilution
The macro tape is mildly constructive (VIX 16, S&P near highs, neutral-to-tailwind regime) and IBM's low 0.68 beta means the market backdrop is neither helping nor hurting much - this is not a name that rides risk-on euphoria or gets crushed in risk-off. So the pressure here is almost entirely idiosyncratic and narrative-driven, and the narrative is unfavorable. IBM's archetype is 'steady compounder' with minimal intensity and low cult - meaning there is no story bid supporting the stock, no marginal buyer chasing it for a dream. Meanwhile the dominant market narrative is AI hyperscaler growth, and the news flow is explicitly framing IBM as the loser of that comparison (Alphabet at $119B revenue vs IBM 'volatile around $17B'). The July 14 preliminary Q2 warning - a 25% single-day plunge on customers reallocating spend from software to AI hardware - is the freshest and most damaging sentiment anchor, and it directly validates the bear frame. Cramer publicly lamenting the name, YTD down 23%, and coverage tone leaning skeptical all reinforce a negative drift. The quantum breakthrough headlines are a small offset - a potential story seed - but intensity is minimal and the market is not yet paying for it. Analyst tone appears cautious post-warning. Net: a persistent, ordinary-to-real headwind on a low-beta name where the macro can't rescue it and no counter-narrative exists.
Verify before trusting this (4)
- Whether the quantum-advantage story gains analyst upgrades or price-target revisions - the only visible path to narrative rehabilitation
- Q2 actual print and guide vs the July 14 warning - a second miss would deepen the headwind, an in-line print could stabilize tone
- Any rotation into low-beta dividend defensives if the tape turns risk-off, which would disproportionately help IBM
- Sell-side tone shift: consensus target revisions post-warning and any downgrades still to come
This lens hasn't been run for this ticker yet.
When we made this prediction on Aug 3, 2026, IBM was $223.65. We expect it to be $238.20 by Feb 2027, and we consider it great value under $185.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 3, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.